 |
71 Diseases |  |
125 Trials |
|
125 Trials |  |
3027 News |  |
| 12345678910111213...4142» |
- | Halaven (eribulin mesylate) / Eisai, tolinapant (ASTX660) / Otsuka
Enrollment change, Trial withdrawal: Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 2, 2025
P1, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
N=42 --> 0 | Suspended --> Withdrawn
- ||||| izalontamab brengitecan (BL-B01D1) / Biokin Pharma, BMS
Enrollment closed: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer (clinicaltrials.gov) - Jun 26, 2025
P3, N=383, Active, not recruiting, Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
N=42 --> 0 | Suspended --> Withdrawn Recruiting --> Active, not recruiting
- || Halaven (eribulin mesylate) / Eisai
Clinical, Journal, Real-world evidence: Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study. (Pubmed Central) - Jun 24, 2025
The most frequently observed adverse events were hematological toxicity, with the majority classified as manageable in severity. The findings emphasize the potential of Eribulin in the treatment of HER2-negative advanced breast cancer, highlighting the need for further large-scale, prospective studies to refine and enhance treatment strategies.
- | Halaven (eribulin mesylate) / Eisai, farletuzumab ecteribulin (MORAb-202) / Eisai
Preclinical, Journal: Antitumor Effect of Farletuzumab ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models. (Pubmed Central) - Jun 23, 2025
expression alone. These findings support further clinical development of FZEC for EC treatment and highlight the complexity of the mechanisms of action of ADCs.
- ||||| evorpacept (ALX148) / ALX Oncology
New P1/2 trial: ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies (clinicaltrials.gov) - Jun 6, 2025
P1/2, N=280, Recruiting, Sponsor: ALX Oncology Inc.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Anlotinib Combined with Chemotherapy in HER2-Negative Advanced Breast Cancer Post Standard Therapy Failure: A Prospective Multicenter Clinical Study (EUDRACT) - Jun 6, 2025
P2, N=110, Not yet recruiting, Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- | Halaven (eribulin mesylate) / Eisai
New P4 trial: The effect of prolonged analgesia with Eribulin on postoperative pain and knee function in patients undergoing total knee arthroplasty: a prospective randomized controlled study. (EUDRACT) - Jun 5, 2025
P4, N=80, Not yet recruiting, Sponsor: Xi'an Honghui hospital; Xi'an Honghui hospital
- |||||| BL-M07D1 / Biokin Pharma
Enrollment open: A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - May 30, 2025
P3, N=564, Recruiting, Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
These findings support further clinical development of FZEC for EC treatment and highlight the complexity of the mechanisms of action of ADCs. Not yet recruiting --> Recruiting
- ||| Halaven (eribulin mesylate) / Eisai
Journal, Adverse events, Monotherapy: The Effectiveness and Adverse Events of Eribulin Monotherapy in Indonesian Metastatic Breast Cancer (MBC) Patients. (Pubmed Central) - May 29, 2025
This study suggests that eribulin monotherapy is associated with disease control and survival benefits in Indonesian MBC patients while maintaining a manageable safety profile. However, further prospective studies are needed to confirm its long-term efficacy, impact beyond 6 cycles, and comparative effectiveness relative to other chemotherapy regimens.
- || Halaven (eribulin mesylate) / Eisai, farletuzumab ecteribulin (MORAb-202) / Eisai
PK/PD data, Journal: Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors. (Pubmed Central) - May 27, 2025
However, further prospective studies are needed to confirm its long-term efficacy, impact beyond 6 cycles, and comparative effectiveness relative to other chemotherapy regimens. Dosing simulations showed that BSA-based dosing (33 mg/m2) yielded similar tumor responses to BW-based dosing (0.9
- | Halaven (eribulin mesylate) / Eisai
Journal, Monotherapy: Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy. (Pubmed Central) - May 20, 2025
Dosing simulations showed that BSA-based dosing (33 mg/m2) yielded similar tumor responses to BW-based dosing (0.9 Eribulin shows promising effects of unresectable/metastatic ACC, offering tolerable adverse events.
- | Preclinical, Journal: Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers. (Pubmed Central) - May 18, 2025
Cross-resistance levels were lowest for the CHK2 inhibitor CCT241533, the PLK1 inhibitor SBE13, and the RAD51 recombinase inhibitor B02, suggesting that CHK2, PLK1, and RAD51 are potential drug targets for therapy-refractory TNBC. In conclusion, we present novel preclinical models of acquired drug resistance in TNBC and the identification of novel candidate therapeutic targets and biomarkers for this disease.
- | Halaven (eribulin mesylate) / Eisai
Journal: Eribulin-induced pulmonary toxicity mimicking metastatic lung disease. (Pubmed Central) - May 17, 2025
In conclusion, we present novel preclinical models of acquired drug resistance in TNBC and the identification of novel candidate therapeutic targets and biomarkers for this disease. No abstract available
- | Halaven (eribulin mesylate) / Eisai
Observational data, Retrospective data, Journal: Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study. (Pubmed Central) - May 17, 2025
Notably, the response and PFS were independent of hepatic metastasis, suggesting benefit across various MBC subtypes, including those with liver involvement. However, the retrospective design warrants cautious interpretation, and further prospective studies are needed to confirm these findings and optimize eribulin's use, potentially through molecular profiling for personalized treatment strategies.
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed: Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (clinicaltrials.gov) - May 15, 2025
P3, N=246, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
However, the retrospective design warrants cautious interpretation, and further prospective studies are needed to confirm these findings and optimize eribulin's use, potentially through molecular profiling for personalized treatment strategies. Not yet recruiting --> Active, not recruiting
- ||||| OQY-3258 / Oqory
Trial initiation date: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - May 14, 2025
P3, N=504, Not yet recruiting, Sponsor: Shanghai Escugen Biotechnology Co., Ltd
Not yet recruiting --> Active, not recruiting Initiation date: Feb 2025 --> Sep 2025
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Enrollment closed, Trial completion date: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - May 14, 2025
P1/2, N=28, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Feb 2025 --> Sep 2025 Completed --> Active, not recruiting | Trial completion date: Mar 2024 --> May 2026
- ||| pazopanib / Generic mfg., Halaven (eribulin mesylate) / Eisai, doxorubicin hydrochloride / Generic mfg.
Journal, Adverse events: Adverse Outcome of a Solitary Fibrous Tumor Originating in the Bladder. (Pubmed Central) - May 8, 2025
There are no effective systemic treatments for solitary fibrous tumors, which can lead to poor outcomes. Individualized treatment approaches are necessary.
- |||||||||| BL-M07D1 / Biokin Pharma
New P3 trial: A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - May 6, 2025
P3, N=564, Not yet recruiting, Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- | Halaven (eribulin mesylate) / Eisai, paclitaxel / Generic mfg., capecitabine / Generic mfg.
Journal: Immune and Metabolic Reprogramming Induced by Paclitaxel, Capecitabine and Eribulin in Breast Cancer: Insights into Therapeutic Targets. (Pubmed Central) - May 5, 2025
Distinct patterns of metabolic and immune dysregulation were associated with resistance to eribulin, capecitabine and paclitaxel. Varied immune and metabolic profiles were specific to each of the three chemotherapies, representing potential novel, and individualized, points of therapeutic leverage.
- || BNT327 / BioNTech
Trial completion date, Trial primary completion date: BNT327-02: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (clinicaltrials.gov) - May 1, 2025
P2, N=70, Recruiting, Sponsor: BioNTech SE
Varied immune and metabolic profiles were specific to each of the three chemotherapies, representing potential novel, and individualized, points of therapeutic leverage. Trial completion date: Jan 2027 --> Sep 2028 | Trial primary completion date: Mar 2025 --> Nov 2027
- BB-1701 / BlissBio
A phase II study to evaluate the safety and efficacy of BB-1701 in subjects with HER2 expression locally advanced/metastatic breast cancer previously treated with HER2-ADC containing TOP-I inhibitor. (Hall A - Posters and Exhibits; Poster Bd #: 72) - May 1, 2025 - Abstract #ASCO2025ASCO_7314;
P
Clinical Trial Registration Number: CTR20241422 Background: BB-1701 is an HER2-targeting antibody-drug conjugate (ADC) containing eribulin...Among 8 HER2 low-expressioning (IHC 1+) patients, 3 patients achieved PR (2 patients received prior trastuzumab deruxtecan and 1 patient received prior SHR-A1811) and 4 patients had SD with DCR of 87.5%. BB-1701 shows promising antitumor activity and a manageable safety profile in HER2 expressing breast cancer patients who had previously been treated with HER2-ADC (containing TOP-I inhibitor).
- || Halaven (eribulin mesylate) / Eisai
P4 data, Journal, Real-world evidence: Safety and Effectiveness of Eribulin in Patients with Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes in Real-World Clinical Practice: A 6-Year Post-Marketing Surveillance Study in South Korea. (Pubmed Central) - Apr 30, 2025
Overall response and disease control rates were 31.7% and 95.6%, respectively, and the median duration of eribulin use (time to treatment failure) was 3.0 months. This large real-world PMS analysis in patients with advanced or metastatic breast cancer demonstrated the effectiveness of eribulin and found no new safety concerns relative to safety information from prior clinical and real-world studies, and approvals in South Korea and other countries.
- |||| JSKN016 / Alphamab
New P1/2 trial: Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - Apr 25, 2025
P1/2, N=180, Not yet recruiting, Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Yondelis (trabectedin) / PharmaMar, J&J, Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Cellular proliferation and tumor suppression pathways as potential targets in clinically aggressive sarcomas. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_7172;
The presence of genomic alterations in cell proliferation and tumor suppression pathways could also be early indicators of disease aggressiveness if closely monitored. With only a few selected fusions currently crucial in sarcomas, this study extends the molecular repertoire for practice.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Herceptin (trastuzumab) / Roche
Real-world clinical outcome of trastuzumab derutexcan (T-DXd) in metastatic breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6945;
A considerable amount of cross-resistance of SG use immediately after T-DXd was observed. Notably, the presence of brain metastases and TP53 mutations were associated with worse PFS in HER2-low cohort.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Real-world clinical outcome of sacituzumab govitecan (SG) in HER2-negative metastatic breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4182;
SG demonstrated better PFS when used earlier in the treatment sequence, particularly in HR+HER2- cohort. Genomic profiling revealed TP53 mutations trended toward improved PFS.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trodelvy use in advanced triple negative breast cancer in Australia (TRACIE): Study design and interim analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4170;
Interim analysis of real-world data for advanced TNBC patients treated with SG demonstrate encouraging PFS and OS in an aggressive breast cancer subtype, comparable to the ASCENT clinical trial, with acceptable tolerability and no unexpected toxicity. Future presentation of treatment outcomes including subgroup analysis is warranted.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A new option for post-CDK4/6is resistance era? Multicenter real-world study of anlotinib-based combination therapy in hormone receptor-positive metastatic breast cancer resistant to CDK4/6 inhibitors. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4047;
P
Combination agents included eribulin, nab-paclitaxel, etoposide, capecitabine, pembrolizumab, sintilimab, or fulvestrant, among others. Anlotinib-based combination therapy has demonstrated good efficacy and acceptable safety in HR+/HER2- MBC patients previously treated with CDK4/6is, making it a viable treatment option following resistance to CDK4/6is.
- Comparative efficacy of PARP inhibitors in BRCA mutated HER2-negative breast cancer: A systematic review and network meta-analysis of randomized controlled trials. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4038;
Veliparib combined with SOC showed the highest OS improvement, while niraparib ranked highest for PFS, followed by talazoparib and olaparib. Further trials are needed to confirm these findings and refine treatment strategies for BRCAm, HER2-BC.
- Trastuzumab-pertuzumab combined with taxanes or eribulin in HER2-positive breast cancer: A single-arm meta-analysis of RCTs. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4036;
This meta-analysis highlights the differential mortality rates and a spectrum of adverse events associated with trastuzumab-pertuzumab combined with taxanes or eribulin in HER2-positive breast cancer patients, influenced by prior therapy status and age. These findings underscore the need for personalized treatment strategies to optimize efficacy and manage toxicities effectively.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Eribulin plus pyrotinib In trastuzumab-resistant HER2-positive advanced breast cancer: A single-arm, multicenter phase II trial (EPIC trial). (Hall A - Posters and Exhibits; Poster Bd #: 10) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3405;
P4
The combination of eribulin and pyrotinib shows promise as a therapeutic option for patients with HER2-positive advanced breast cancer resistant to trastuzumab. While advancements in anti-HER2 therapies continue, further studies are needed to address unresolved challenges in this clinical context.
- TQB2930 / Sino Biopharm
Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ?2 line treatments: Results from a phase 1b/2 study. (Hall A - Posters and Exhibits; Poster Bd #: 12) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3381;
P1/2
The combination of TQB2930 with chemotherapy demonstrates encouraging antitumor efficacy and an acceptable safety profile in patients with HER2-positive BC who have undergone at least two prior lines of treatment. These results support the potential of TQB2930 as a novel therapeutic strategy for HER2-positive BC and underscore the need for further clinical exploration.
- Xtandi (enzalutamide) / Pfizer, Astellas, Mifeprex (mifepristone) / Danco Laboratories
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769). (Hall A - Posters and Exhibits; Poster Bd #: 110a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3319;
P2
Tumors must have AR >10%, normal organ function, no history of brain mets. As of 1/23/25, 11 of 201 pts have begun protocol-specified tx.
- cisplatin/vinblastine/SHAO-FA (INT230-6) / Intensity Therap
A multicenter, randomized, global phase 3 study to assess the efficacy and safety of intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as monotherapy compared with standard of care systemic chemotherapy in adults with locally recurrent, inoperable, or metastatic soft tissue sarcomas (STS; INVINCIBLE-3). (Hall A - Posters and Exhibits; Poster Bd #: 66a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2050;
P3
Bilirubin (BR) ? 1.5
- Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Eribulin plus anlotinib in advanced soft tissue sarcoma (ERAS): Updates on efficacy and biomarkers. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2024;
P2
The lipid metabolism level in sarcomas could serve as a biomarker for the efficacy of this treatment regimen, potentially providing new insights into L-type sarcomas. Results of a 1:2 propensity score matching analysis.* Fisher's Exact Test.
- | Ontruzant (trastuzumab-dttb) / Samsung, AffaMed Therap, Mundipharma, Organon, Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: ESPERO: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (clinicaltrials.gov) - Apr 17, 2025
P2, N=180, Recruiting, Sponsor: Seoul National University Hospital
Results of a 1:2 propensity score matching analysis.* Fisher's Exact Test. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Feb 2024 --> Dec 2026
- || Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Journal: Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (Pubmed Central) - Apr 15, 2025
The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies.
- | Halaven (eribulin mesylate) / Eisai, paclitaxel / Generic mfg.
Journal: Symptomatic bone marrow metastasis in triple-negative breast cancer: a case report and literature review. (Pubmed Central) - Apr 14, 2025
The patient received paclitaxel and eribulin chemotherapy combined with transfusion support, achieving significant symptom control. This rare case highlights the importance of early detection and aggressive management in TNBC with bone marrow metastasis.
- | Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal: Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters. (Pubmed Central) - Apr 12, 2025
Nomograms incorporating peripheral blood parameters may improve the accuracy of predicting OS and PFS in patients treated with eribulin. Our prediction model may help decision-making for breast cancer patients who are considering eribulin treatment.
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Journal: Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin. (Pubmed Central) - Apr 10, 2025
P2
Notably, B. fragilis NCTC 9343 supernatant induced dose-dependent lactate dehydrogenase (LDH) release from the MCF-7 (HR-positive/HER2-negative) BC cell line. These findings suggest that specific gut and oral microbiota may modulate the effectiveness of combinatory anti-BC therapies, potentially through the action of microbial metabolites.
- ||| P3 data, Journal, Head-to-Head: Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial. (Pubmed Central) - Apr 7, 2025
P3
These findings suggest that specific gut and oral microbiota may modulate the effectiveness of combinatory anti-BC therapies, potentially through the action of microbial metabolites. The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.
- Halaven (eribulin mesylate) / Eisai
Efficacy and safety of eribulin in liposarcoma and leiomyosarcoma: A systematic review and meta-analysis (Villa Ciani) - Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_257;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- Yondelis (trabectedin) / PharmaMar, J&J, Halaven (eribulin mesylate) / Eisai
Eribulin (E) versus trabectedin (T) therapy in patients with advanced liposarcoma: Efficacy comparison using real-world data evidence from TriNetX platform (Hall A) - Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_43;
Legal entity responsible for the study J. Rodriguez Pascual. Funding Has not received any funding.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Trial completion, Enrollment change: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Apr 3, 2025
P1/2, N=28, Completed, Sponsor: National Cancer Institute (NCI)
Funding Has not received any funding. Active, not recruiting --> Completed | N=106 --> 28
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Clinical Study on the Efficacy of Immunotherapy Combined with Targeted Therapy and Chemotherapy Versus Investigator's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=246, Not yet recruiting, Sponsor: Sun Yat-sen Memorial Hospital Sun Yat-sen University; Sun Yat-sen Memorial Hospital Sun Yat-sen University
- | pazopanib / Generic mfg., Halaven (eribulin mesylate) / Eisai
Journal: Case Report: an extremely rare case of giant dedifferentiated retroperitoneal liposarcoma. (Pubmed Central) - Apr 1, 2025
Ongoing clinical trials suggest a shift towards multimodal therapy. This case report reports the largest retroperitoneal liposarcoma and underscores the complexity of managing retroperitoneal DDL.
- Halaven (eribulin mesylate) / Eisai
Chemotherapy versus endocrine therapy after progression on first-line CDK 4/6 inhibitors in metastatic breast cancer (Hall B0) - Mar 29, 2025 - Abstract #ESMOBC2025ESMO_BC_644;
This case report reports the largest retroperitoneal liposarcoma and underscores the complexity of managing retroperitoneal DDL. Endocrine regimens were administered in 74 pts (53.2%): ET + everolimus
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai
Efficacy of sequential antibody-drug conjugates (ADCs) targeting topoisomerase-1 in HER2-low metastatic breast cancer (MBC): Updated results and additional analyses from the French multicenter retrospective ADC-low cohort (Hall B0) - Mar 29, 2025 - Abstract #ESMOBC2025ESMO_BC_585;
Multivariate analysis suggested a better benefit for pts receiving T-DXd rather than SG as ADC2. The use of non-targeted cytotoxics, such as eribuline, appears to be a relevant therapeutic option after progression to ADC1, allowing a relatively similar disease control time as ADC2.
- Halaven (eribulin mesylate) / Eisai
Long-term outcomes of eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer: Results of the randomized JBCRG-22 study (Hall B0) - Mar 29, 2025 - Abstract #ESMOBC2025ESMO_BC_504;
The use of non-targeted cytotoxics, such as eribuline, appears to be a relevant therapeutic option after progression to ADC1, allowing a relatively similar disease control time as ADC2. Group A pts (aged 90%.